RecruitingPhase 3NCT04975178

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa

Studying Tuberculosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Biofabri, S.L
Principal Investigator: Mark Hatherill
University of Cape Town, Faculty of Health Sciences
Intervention: MTBVAC(biological)
Enrollment: 7120 enrolled
Eligibility: All sexes
Timeline: 2022 – 2029

Study locations (1)

South African Tuberculosis Initiative, Brewelskloof Hospital, Worcester, Western Cape, South Africa

Collaborators

TuBerculosis Vaccine Initiative · University of Cape Town · Institut Pasteur de Madagascar · Biomedical Research Center EPLS · Universidad de Zaragoza · University of Stellenbosch · University of KwaZulu · Wits Health Consortium (Pty) Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04975178 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis →

← Back to all trials